Guardant Health Inc. (GH) | Rumor.io

Guardant Health

Attention (50-day avg)0%

Attention rank (50-day avg)#745

Bullish sentiment (50-day avg)100%

Price to earnings ratio-53.4

Market capitalization23.8B

Earnings per share-3.51

Dividend yield (TTM)—

Revenue (annual)982M

Net income (annual)-416.3M

Social

What share of all stock conversation is about GH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.11	0.02% +0.01	0% 0	0% 0

Jul 1

Guardant Health's stock has surged to a more than 5-year high after UnitedHealth announced it will begin offering insurance coverage for the company's colorectal cancer test starting August 1.
The news has driven strong investor reaction, with the stock rallying and some investors reporting gains of over 100% on their initial investments.
The $GH $NTRA duo has been identified as a super strong performer, with Guardant Health's shares continuing to rise and approaching previous all-time highs.

Generated by AI

Sentiment

Of the messages about GH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	99.89% +0.04	98.14% +5.04
Bearish	—	0%	0.11% -0.04	1.86% -5.04

Bullish· Oct 30

Guardant Health, Inc. has reported 39% revenue growth in Q3 2025, narrowing losses and increasing full-year guidance to $965-970M.
The company is expected to see significant share gains in the liquid biopsy market, driven by the capabilities of its 360 test and the growth of concurrent testing.
With strong fundamentals and institutional support, Guardant Health's stock is likely to continue moving higher, with some analysts predicting a price target of $100.

Bearish· Dec 16

The company's clinical data led to a 40% after-hours drop in the stock's price.
The high cost of the company's colorectal cancer screening test, Shield, may be a barrier to adoption and is raising concerns about the company's future.
The company's recent trial results were disappointing, leading to a significant drop in the stock price and raising questions about the company's ability to turn a profit.

Generated by AI

Topics

Of the messages about GH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	5.31%	27.11%	3.37%
Technical Analysis	—	94.69%	72.44%	22.4%
Analysts	—	0%	0.44%	35.99%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	2.46%
Macro	—	0%	0%	35.74%

Earnings· May 7

Guardant Health ($GH) reported Q1 2020 revenue of $67.5 million, a 84% increase year-over-year, and a gross margin of 70%.
The company's earnings per share (EPS) of $0.29 beat the estimate of $0.39, and revenue of $67.5 million beat the estimate of $56.47 million.
Guardant Health's Q1 2020 results were driven by strong demand for its liquid biopsy tests, with 15,257 tests reported to clinical customers and 5,266 tests reported to biopharmaceutical customers.

Analysts· Feb 24

Citigroup analyst Patrick Donnelly lowered the price target for Guardant Health to $120, maintaining a Buy rating.
Morgan Stanley analyst lowered the price target for Guardant Health to $120, maintaining an Overweight rating.
Wells Fargo analyst Dan Leonard lowered the price target for Guardant Health to $115, maintaining an Overweight rating.

Announcements· Oct 15

Guardant Health is not mentioned in this post, which primarily discusses Mainz Biomed and its product ColoAlert.

Technical Analysis· May 10

$GH has formed a triple top breakout, with a potential price target of $111 and a relative strength index (RSI) of 60.24.
The stock has broken above its 50-day moving average after reporting accelerated sales growth, with a potential resistance area near $80.
$GH has been identified as a potential swing trade, with a recent earnings report beating expectations and a target raise, accompanied by a breakout from a bull flag pattern.

Generated by AI

Community

Of the messages about GH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	17.96%	44.1%	31.08%
Newcomers	100%	82.04%	55.9%	68.92%

Regulars· Jan 6

Guardant Health's stock rating has been lowered by Evercore ISI, citing concerns about the company's growth prospects and valuation.
The stock's price has increased by 7.38% to $109.23, and the author notes that the price action is setting up nicely, potentially leading to a sector move.
The author has taken a position in Guardant Health, citing a clean weekly base and a 12% move over 6 weeks, which is part of a larger 100% increase in 3 months, and is now considering adding to the position.

Newcomers· Nov 24

The newcomer is focusing on the price movement of Guardant Health, noting a 5% increase since a YouTube video mention.
The newcomer is observing that biotechnology stocks are trending lately, and Guardant Health is part of this trend.
The newcomer is interested in the potential of Guardant Health's ctDNA technology, suggesting it may be a key component in future guidelines.

Generated by AI

News

AI-Fueled Precision Oncology Firm Diagnoses Breakout Move

Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.

8d agoInvestor's Business Daily

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...

12d agoYahoo Finance

Cathie Wood’s ARK increases stake in Guardant Health stock

12d agoInvesting.com

Dow Slides 600 Points On Rate Hike, Hawkish Warsh; Guardant, Apple, Twilio Eye Buy Points

The Dow Jones index sold off more than 600 points Wednesday after the Fed's rate hike and Fed Chair Kevin Warsh's hawkish comments.

13d agoInvestor's Business Daily

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

13d agoYahoo Finance

Guardant Health Nears Buy Point As Sales Outlook Brightens

Guardant Health provides services across the cancer continuum as its stock nears a buy point of 176.58 after a breakout.

13d agoInvestor's Business Daily

Also Discussed

Investors talking about GH also mention

#	Name	Attention
1	EXAS - Exact Sciences Corporation	——
2	Natera, Inc.NTRA	0%-0.01
3	Illumina Inc.ILMN	0%+0
4	10x Genomics Inc. Class A Common StockTXG	0%-0.02
5	Personalis Inc.PSNL	0%-0.01
6	Myriad Genetics Inc.MYGN	0%0
7	GRAIL, Inc.GRAL	0%+0
8	Thermo Fisher Scientific Inc.TMO	0%0
9	NVTA - Invitae Corporation	——
10	Mainz Biomed N.V.MYNZ	0%new

Guardant Health Inc.

Healthcare
Diagnostics & Research

Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions. Its product portfolio includes liquid biopsy tests for tumor mutation profiling, molecular residual disease monitoring, tissue-based genomic profiling, and colorectal cancer screening. The company’s solutions are used across clinical care and research settings to help identify biomarkers, track recurrence, and provide molecular insights from tumor-derived material. Guardant Health serves healthcare providers, laboratories, researchers, and life sciences partners in the United States and internationally, with a focus on noninvasive diagnostics and cancer monitoring. Headquartered in Palo Alto, California, Guardant Health plays a significant role in the growing market for precision medicine and advanced oncology diagnostics.

Website

Location

3100 Hanover Street

Palo Alto, CA, 94304

United States

Social

What share of all stock conversation is about GH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.11	0.02% +0.01	0% 0	0% 0

Jul 1

Guardant Health's stock has surged to a more than 5-year high after UnitedHealth announced it will begin offering insurance coverage for the company's colorectal cancer test starting August 1.
The news has driven strong investor reaction, with the stock rallying and some investors reporting gains of over 100% on their initial investments.
The $GH $NTRA duo has been identified as a super strong performer, with Guardant Health's shares continuing to rise and approaching previous all-time highs.

Generated by AI

Sentiment

Of the messages about GH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	99.89% +0.04	98.14% +5.04
Bearish	—	0%	0.11% -0.04	1.86% -5.04

Bullish· Oct 30

Guardant Health, Inc. has reported 39% revenue growth in Q3 2025, narrowing losses and increasing full-year guidance to $965-970M.
The company is expected to see significant share gains in the liquid biopsy market, driven by the capabilities of its 360 test and the growth of concurrent testing.
With strong fundamentals and institutional support, Guardant Health's stock is likely to continue moving higher, with some analysts predicting a price target of $100.

Bearish· Dec 16

The company's clinical data led to a 40% after-hours drop in the stock's price.
The high cost of the company's colorectal cancer screening test, Shield, may be a barrier to adoption and is raising concerns about the company's future.
The company's recent trial results were disappointing, leading to a significant drop in the stock price and raising questions about the company's ability to turn a profit.

Generated by AI

Topics

Of the messages about GH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	5.31%	27.11%	3.37%
Technical Analysis	—	94.69%	72.44%	22.4%
Analysts	—	0%	0.44%	35.99%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	2.46%
Macro	—	0%	0%	35.74%

Earnings· May 7

Guardant Health ($GH) reported Q1 2020 revenue of $67.5 million, a 84% increase year-over-year, and a gross margin of 70%.
The company's earnings per share (EPS) of $0.29 beat the estimate of $0.39, and revenue of $67.5 million beat the estimate of $56.47 million.
Guardant Health's Q1 2020 results were driven by strong demand for its liquid biopsy tests, with 15,257 tests reported to clinical customers and 5,266 tests reported to biopharmaceutical customers.

Analysts· Feb 24

Citigroup analyst Patrick Donnelly lowered the price target for Guardant Health to $120, maintaining a Buy rating.
Morgan Stanley analyst lowered the price target for Guardant Health to $120, maintaining an Overweight rating.
Wells Fargo analyst Dan Leonard lowered the price target for Guardant Health to $115, maintaining an Overweight rating.

Announcements· Oct 15

Guardant Health is not mentioned in this post, which primarily discusses Mainz Biomed and its product ColoAlert.

Technical Analysis· May 10

$GH has formed a triple top breakout, with a potential price target of $111 and a relative strength index (RSI) of 60.24.
The stock has broken above its 50-day moving average after reporting accelerated sales growth, with a potential resistance area near $80.
$GH has been identified as a potential swing trade, with a recent earnings report beating expectations and a target raise, accompanied by a breakout from a bull flag pattern.

Generated by AI

Community

Of the messages about GH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	17.96%	44.1%	31.08%
Newcomers	100%	82.04%	55.9%	68.92%

Regulars· Jan 6

Guardant Health's stock rating has been lowered by Evercore ISI, citing concerns about the company's growth prospects and valuation.
The stock's price has increased by 7.38% to $109.23, and the author notes that the price action is setting up nicely, potentially leading to a sector move.
The author has taken a position in Guardant Health, citing a clean weekly base and a 12% move over 6 weeks, which is part of a larger 100% increase in 3 months, and is now considering adding to the position.

Newcomers· Nov 24

The newcomer is focusing on the price movement of Guardant Health, noting a 5% increase since a YouTube video mention.
The newcomer is observing that biotechnology stocks are trending lately, and Guardant Health is part of this trend.
The newcomer is interested in the potential of Guardant Health's ctDNA technology, suggesting it may be a key component in future guidelines.

Generated by AI

Guardant Health

Social

Jul 1

Bullish· Oct 30

Bearish· Dec 16

Earnings· May 7

Analysts· Feb 24

Announcements· Oct 15

Technical Analysis· May 10

Regulars· Jan 6

Newcomers· Nov 24

AI-Fueled Precision Oncology Firm Diagnoses Breakout Move

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Cathie Wood’s ARK increases stake in Guardant Health stock

Dow Slides 600 Points On Rate Hike, Hawkish Warsh; Guardant, Apple, Twilio Eye Buy Points

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health Nears Buy Point As Sales Outlook Brightens

Also Discussed

Guardant Health Inc.

Company Information

Location

AI-Fueled Precision Oncology Firm Diagnoses Breakout Move

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Cathie Wood’s ARK increases stake in Guardant Health stock

Dow Slides 600 Points On Rate Hike, Hawkish Warsh; Guardant, Apple, Twilio Eye Buy Points

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health Nears Buy Point As Sales Outlook Brightens

Also Discussed

Social

Jul 1

Bullish· Oct 30

Bearish· Dec 16

Earnings· May 7

Analysts· Feb 24

Announcements· Oct 15

Technical Analysis· May 10

Regulars· Jan 6

Newcomers· Nov 24